Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
PGRMC2 Biologics Sequence Review Report 2026: Membrane-associated progesterone receptor component 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PGRMC2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LDLRAD4 Biologics Sequence Review Report 2026: Low-density lipoprotein receptor class A domain-containing protein 4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of LDLRAD4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MUSK Biologics Sequence Review Report 2026: Muscle, skeletal receptor tyrosine-protein kinase Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of MUSK protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NCR3 Biologics Sequence Review Report 2026: Natural cytotoxicity triggering receptor 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of NCR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FFAR3 Biologics Sequence Review Report 2026: Free fatty acid receptor 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FFAR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FFAR1 Biologics Sequence Review Report 2026: Free fatty acid receptor 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FFAR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GABRD Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit delta Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GABRD protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IRS4 Biologics Sequence Review Report 2026: Insulin receptor substrate 4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IRS4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GOSR2 Biologics Sequence Review Report 2026: Golgi SNAP receptor complex member 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GOSR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PEX7 Biologics Sequence Review Report 2026: Peroxisomal targeting signal 2 receptor Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PEX7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GABRP Biologics Sequence Review Report 2026: Gamma-aminobutyric acid receptor subunit pi Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GABRP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PITPNM1 Biologics Sequence Review Report 2026: Membrane-associated phosphatidylinositol transfer protein 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PITPNM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.